利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

12 条记录 (耗时 0.03 秒)

    Cyclopentane derivatives
    2.
    发明授权
    Cyclopentane derivatives 失效
    环戊烷衍生物

    公开(公告)号：US5155112A

    公开(公告)日：1992-10-13

    申请号：US617160

    申请日：1990-11-23

    申请人： Richard Storer ,  Ian L. Paternoster ,  Alan D. Borthwick ,  Keith Biggadike

    发明人： Richard Storer ,  Ian L. Paternoster ,  Alan D. Borthwick ,  Keith Biggadike

    IPC分类号： C07D473/00

    CPC分类号： C07D473/00

    摘要： The present invention provides the compounds of formula (I) ##STR1## and salts and solvates thereof wherein R.sup.1 represents a hydrogen or fluorine atom or a hydroxy group, R.sup.2 represents a fluorine atom or a hydroxyl or C.sub.1-6 alkoxy group and B represents a purine base, and describes processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of viral infections, particularly those caused by the Herpetoviridae.

    摘要翻译： 本发明提供式（I）化合物及其盐和溶剂化物，其中R1表示氢或氟原子或羟基，R2表示氟原子或羟基或C1-6烷氧基，B表示 代表嘌呤碱，并描述其制备方法，含有它们的药物组合物及其在治疗病毒感染中的用途，特别是由疱疹病毒科引起的病毒感染。

    1,4-Dihydro pyridine 3,5 dicarboxylic acid derivatives and compositions
    3.
    发明授权
    1,4-Dihydro pyridine 3,5 dicarboxylic acid derivatives and compositions 失效
    1,4-二氢吡啶3.5二羧酸衍生物和组合物

    公开(公告)号：US4806533A

    公开(公告)日：1989-02-21

    申请号：US16590

    申请日：1987-02-19

    申请人： Claudio Semeraro ,  Dino Micheli ,  Daniele Pieraccioli ,  Giovanni Gaviraghi ,  Alan D. Borthwick

    发明人： Claudio Semeraro ,  Dino Micheli ,  Daniele Pieraccioli ,  Giovanni Gaviraghi ,  Alan D. Borthwick

    IPC分类号： A61K31/455 ,  A61P9/00 ,  C07D211/90 ,  A61K31/535 ,  C07D401/06 ,  C07D413/06

    CPC分类号： C07D211/90

    摘要： Compounds are described of the formula ##STR1## wherein R.sub.1 and R.sub.4 independently represent a C.sub.1-4 alkyl group;R.sub.2 and R.sub.3 independently represent a C.sub.1-6 straight or branched alkyl chain or alkoxy group;R.sub.5 represents a straight or branched chain C.sub.1-13 alkyl group or a C.sub.5-8 cycloalkyl group which may be substituted by a C.sub.1-3 alkyl substituent;R.sub.6 represents a halogen atom or a straight or branched C.sub.1-3 alkyl group.R.sub.7 represents a C.sub.1-4 alkyl group [optionally substituted by hydroxy, C.sub.1-3 alkoxy or trifluoromethyl or by a group NR.sub.8 R.sub.9 where NR.sub.8 R.sub.9 forms a saturated 5 to 7 membered ring optionally containing an additional heleroatom which is oxygen]; or R.sub.7 represents a phenylC.sub.1-2 alkyl group in which the phenyl portion is optionally substituted by 1 to 3 C.sub.1-3 alkyl or C.sub.1-3 alkoxy groups or halogen atoms.The compounds represented by formula (I) reduce intracellular calcium ion concentration by limiting transmembranal calcium ion influx and thus may be useful for the treatment of cardiovascular disorders such as hypertension.

    摘要翻译： 描述式（I）的化合物，其中R 1和R 4独立地表示C 1-4烷基; R2和R3独立地表示C1-6直链或支链烷基链或烷氧基; R5表示可被C1-3烷基取代基取代的直链或支链C1-13烷基或C5-8环烷基; R 6表示卤素原子或直链或支链C 1-3烷基。 R 7表示C 1-4烷基[任选被羟基，C 1-3烷氧基或三氟甲基取代，或NR 8 R 9基团，其中NR 8 R 9形成饱和的5至7元环，任选地含有另外的氧原子是氧]。 或R 7表示苯基C 1-2烷基，其中苯基部分任选被1至3个C 1-3烷基或C 1-3烷氧基或卤素原子取代。 由式（I）表示的化合物通过限制跨膜钙离子流入而降低细胞内钙离子浓度，因此可用于治疗心血管疾病如高血压。

    1.4-dihydropyridines
    4.
    发明授权
    1.4-dihydropyridines 失效
    1,4-二氢吡啶

    公开(公告)号：US4935548A

    公开(公告)日：1990-06-19

    申请号：US262240

    申请日：1988-10-21

    申请人： Claudio Semeraro ,  Dino Micheli ,  Daniele Pieraccioli ,  Giovanni Gaviraghi ,  Alan D. Borthwick

    发明人： Claudio Semeraro ,  Dino Micheli ,  Daniele Pieraccioli ,  Giovanni Gaviraghi ,  Alan D. Borthwick

    IPC分类号： A61K31/445 ,  A61K31/451 ,  A61P9/00 ,  C07D211/90

    CPC分类号： C07D211/90

    摘要： Compounds are described of the formula ##STR1## wherein R.sub.1 represents a formyl or nitrile group or a group OCH.sub.2 A where A represents hydroxy, C.sub.1-4 alkoxy or D(CH.sub.2).sub.n NR.sub.7 R.sub.8 (where R.sub.7 and R.sub.8 independently represent hydrogen or C.sub.1-4 alkyl and n is 2 or 3);R.sub.2 and R.sub.3 independently represent a C.sub.1-6 straight or branched alkyl chain or alkoxy group;R.sub.4 represents a C.sub.1-4 alkyl group;R.sub.5 represents a straight or branched chain C.sub.1-13 alkyl group or a C.sub.5-8 cycloalkyl group which may be substituted by a C.sub.1-3 alkyl substituent;R.sub.6 represents a halogen atom or a straight or branched C.sub.1-3 alkyl group.The compounds represented by formula (I) reduce intracellular calcium ion concentration by limiting transmembranal calcium ion influx and thus may be useful for the treatment of cardiovascular disorders such as hypertension.

    摘要翻译： 描述式（I）的化合物，其中R1表示甲酰基或腈基或基团OCH2A，其中A表示羟基，C1-4烷氧基或D（CH2）nNR7R8（其中R7和R8独立地表示氢或C1- 4烷基，n为2或3）; R2和R3独立地表示C1-6直链或支链烷基链或烷氧基; R4代表C1-4烷基; R5表示可被C1-3烷基取代基取代的直链或支链C1-13烷基或C5-8环烷基; R 6表示卤素原子或直链或支链C 1-3烷基。 由式（I）表示的化合物通过限制跨膜钙离子流入而降低细胞内钙离子浓度，因此可用于治疗心血管疾病如高血压。

    Heterocyclic 1,4 dihydropyridine derivatives
    5.
    发明授权
    Heterocyclic 1,4 dihydropyridine derivatives 失效
    杂环1,4二氢吡啶衍生物

    公开(公告)号：US5051432A

    公开(公告)日：1991-09-24

    申请号：US587159

    申请日：1990-09-19

    申请人： Claudio Semeraro ,  Dino Micheli ,  Daniele Pieraccioli ,  Giovanni Gaviraghi ,  Alan D. Borthwick

    发明人： Claudio Semeraro ,  Dino Micheli ,  Daniele Pieraccioli ,  Giovanni Gaviraghi ,  Alan D. Borthwick

    IPC分类号： A61K31/455 ,  A61P9/00 ,  A61P9/10 ,  C07D211/90

    CPC分类号： C07D211/90

    摘要： Compounds are described of the formula ##STR1## wherein R.sub.1 and R.sub.4 independently represent a C.sub.1-4 alkyl group:R.sub.2 represents a group ##STR2## (where A is a bond or a methylene group and R.sub.7 is phenyl C.sub.1-4 alkyl; or R.sub.2 represents a group CH.sub.2 CH.sub.2 NR.sub.8 R.sub.9 (where R.sub.8 is hydrogen or C.sub.1-4 alkyl and R.sub.9 is C.sub.1-4 alkyl, phenyl C.sub.1-4 alkyl or benzoyl C.sub.1-4 alkyl); or R.sub.2 represents a C.sub.1-4 alkyl group substituted by nitrile.R.sub.3 represents a C.sub.1-6 straight or brached alkyl chain or alkoxy group;R.sub.5 represents a straight or branched chain C.sub.1-13 alkyl group or a C.sub.5-8 cycloalkyl group which may be substituted by a C.sub.1-3 alkyl substituent;R.sub.6 represents a halogen atom or a straight or branched C.sub.1-3 alkyl group.The compounds represented by formula (I) reduce intracellular calcium ion concentration by limiting transmembranal calcium ion influx and thus may be useful for the treatment of cardiovascular disorders such as hypertension.

    摘要翻译： 化合物描述为式（I）其中R 1和R 4独立地表示C 1-4烷基：R 2表示基团（其中A是键或亚甲基，R 7是苯基C 1-4烷基 ;或R 2表示基团CH 2 CH 2 NR 8 R 9（其中R 8是氢或C 1-4烷基，R 9是C 1-4烷基，苯基C 1-4烷基或苯甲酰基C 1-4烷基）;或R 2表示被腈取代的C 1-4烷基 R 3表示C 1-6直链或直链烷基或烷氧基; R 5表示可被C 1-3烷基取代基取代的直链或支链C 1-13烷基或C 5-8环烷基; R 6表示 卤素原子或直链或支链C 1-3烷基，由式（I）表示的化合物通过限制跨膜钙离子流入而减少细胞内钙离子浓度，因此可用于治疗心血管疾病如高血压。

    Pyridinedicarboxylic acid derivatives and pharmaceutical compositions
    6.
    发明授权
    Pyridinedicarboxylic acid derivatives and pharmaceutical compositions 失效
    吡啶二羧酸衍生物和药物组合物

    公开(公告)号：US4963571A

    公开(公告)日：1990-10-16

    申请号：US272226

    申请日：1988-11-16

    申请人： Claudio Semeraro ,  Dino Micheli ,  Daniele Pieraccioli ,  Giovanni Gaviraghi ,  Alan D. Borthwick

    发明人： Claudio Semeraro ,  Dino Micheli ,  Daniele Pieraccioli ,  Giovanni Gaviraghi ,  Alan D. Borthwick

    IPC分类号： A61K31/455 ,  A61P9/00 ,  C07D211/90

    CPC分类号： C07D211/90

    摘要： Compounds are described of the formula ##STR1## wherein R.sub.1 and R.sub.4 independently represent a C.sub.1-4 alkyl group;R.sub.2 and R.sub.3 independently represent a C.sub.1-6 straight or branched alkyl chain or alkoxy group;R.sub.5 represents a straight or branched chain C.sub.1-13 alkyl group or a C.sub.5-8 cycloalkyl group which may be substituted by a C.sub.1-3 alkyl substituent;R.sub.6 represents a halogen atom or a straight or branched C.sub.1-3 alkyl group.R.sub.7 represents a C.sub.1-4 alkyl group [optionally substituted by hydroxy, C.sub.1-3 alkoxy or trifluoromethyl or by a group NR.sub.8 R.sub.9 where NR.sub.8 R.sub.9 forms a saturated 5 to 7 membered ring optionally containing an additional heleroatom which is oxygen]; or R.sub.7 represents a phenylC.sub.1-2 alkyl group in which the portion is optionally substituted by 1 to 3 C.sub.1-3 alkyl or C.sub.1-3 alkoxy groups or halogen atoms.The compounds representd by formula (I) reduce intracellular calcium ion concentration by limiting transmembranal calcium ion influx and thus may be useful for the treatment of cardiovascular disorders such as hypertension.

    Heterocyclic compounds and their pharmaceutical formulation
    8.
    发明授权
    Heterocyclic compounds and their pharmaceutical formulation 失效
    杂环化合物及其药物制剂

    公开(公告)号：US5091395A

    公开(公告)日：1992-02-25

    申请号：US270487

    申请日：1988-11-04

    申请人： Claudio Semeraro ,  Dino Micheli ,  Daniele Pieraccioli ,  Giovanni Gaviraghi ,  Alan D. Borthwick

    发明人： Claudio Semeraro ,  Dino Micheli ,  Daniele Pieraccioli ,  Giovanni Gaviraghi ,  Alan D. Borthwick

    IPC分类号： C07D211/90

    CPC分类号： C07D211/90

    摘要： Compounds are described of the formula ##STR1## wherein R.sub.1 and R.sub.4 independently represent a C.sub.1-4 alkyl group;R.sub.2 and R.sub.3 independently represent a C.sub.1-6 straight or branched alkyl chain or alkoxy group;R.sub.5 represents a straight or branched chain C.sub.1-13 alkyl group or a C.sub.5-8 cycloalkyl group which may be substituted by a C.sub.1-3 alkyl substituent;R.sub.6 represents a halogen atom or a straight or branched C.sub.1-3 alkyl group.The compounds represented by formula (I) reduce intracellular calcium ion concentration by limiting transmembranal calcium ion reflux and thus may be useful for the treatment of cardiovascular disorders such as hypertension.

    摘要翻译： 描述式（I）的化合物，其中R 1和R 4独立地表示C 1-4烷基; R2和R3独立地表示C1-6直链或支链烷基链或烷氧基; R5表示可被C1-3烷基取代基取代的直链或支链C1-13烷基或C5-8环烷基; R 6表示卤素原子或直链或支链C 1-3烷基。 由式（I）表示的化合物通过限制跨膜钙离子回流来减少细胞内钙离子浓度，因此可用于治疗心血管疾病如高血压。